The Story of GLP 1

Prijzen vanaf
141,99

Uitgelicht

VERGELIJK ALLE AANBIEDERS (2)

Beschrijving

Bol The Story of GLP-1: A Historical Journey in the Treatment of Diabetes and Obesity offers a compelling narrative about the discovery and development of the hormone GLP-1, which has revolutionized modern approaches to diabetes and obesity. Award-winning scientist Professor Jens Juul Holst, alongside co-authors Professor Sten Madsbad, Professor Jens Meldgaard Bruun, and Novo Nordisk Foundation CEO Mads Krogsgaard Thomsen, trace the scientific breakthroughs and clinical advances that have made GLP-1 therapies, such as Ozempic and Wegovy, essential tools for improving blood sugar control and promoting meaningful, lasting weight loss in patients worldwide. The book explores the rising global prevalence of obesity and diabetes, emphasizing the urgent need for innovative solutions. It critically examines traditional treatments, noting their limitations in sustaining weight loss or reducing complications. The narrative details the paradigm shift brought by GLP-1 medications, including liraglutide and semaglutide, which offer improved cardiovascular outcomes and significant health benefits. The authors also address ongoing challenges of accessibility and affordability, prompting important societal discussions about equitable distribution and funding for these lifechanging therapies.

Vergelijk aanbieders (2)

Shop
Prijs
Verzendkosten
Totale prijs
141,99
Gratis
141,99
Naar shop
Gratis Shipping Costs
155,00
Gratis
155,00
Naar shop
Gratis Shipping Costs
Beschrijving (2)
Bol

The Story of GLP-1: A Historical Journey in the Treatment of Diabetes and Obesity offers a compelling narrative about the discovery and development of the hormone GLP-1, which has revolutionized modern approaches to diabetes and obesity. Award-winning scientist Professor Jens Juul Holst, alongside co-authors Professor Sten Madsbad, Professor Jens Meldgaard Bruun, and Novo Nordisk Foundation CEO Mads Krogsgaard Thomsen, trace the scientific breakthroughs and clinical advances that have made GLP-1 therapies, such as Ozempic and Wegovy, essential tools for improving blood sugar control and promoting meaningful, lasting weight loss in patients worldwide. The book explores the rising global prevalence of obesity and diabetes, emphasizing the urgent need for innovative solutions. It critically examines traditional treatments, noting their limitations in sustaining weight loss or reducing complications. The narrative details the paradigm shift brought by GLP-1 medications, including liraglutide and semaglutide, which offer improved cardiovascular outcomes and significant health benefits. The authors also address ongoing challenges of accessibility and affordability, prompting important societal discussions about equitable distribution and funding for these lifechanging therapies.

Amazon

Pages: 188, Hardcover, Academic Press


Productspecificaties

Merk Elsevier
EAN
  • 9780443332876
Maat


Prijshistorie

* Prijshistorie bevat geen data van Amazon.

Prijzen voor het laatst bijgewerkt op:

Uitgelichte Keuze
141,99
Naar shop